


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Carol W. Readhead and Robert Winston  
 Serial No. Unassigned  
 Filed: November 12, 2001  
 For: TRANSFECTION, STORAGE AND TRANSFER OF MALE GERM  
 CELLS FOR GENERATION OF TRANSGENIC SPECIES

PRELIMINARY AMENDMENT

BOX PATENT APPLICATION  
 Assistant Commissioner for Patents  
 Washington, D.C. 20231

CERTIFICATE OF EXPRESS MAILING		
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office To Addressee" service under 37 CFR 1.10 on the date and label indicated below and is addressed to Box PATENT APPLICATION, The Assistant Commissioner for Patents, Washington, D. C. 20231		
November 12, 2001		EL 900 688 434 US
DATE OF DEPOSIT	SIGNATURE ANN WEISS	EXPRESS MAIL LABEL NO

Dear Sir or Madam:

This Preliminary Amendment is filed with a divisional application of pending U.S. Serial No. 09/191,920, filed November 13, 1999. The divisional application filed herewith is directed to the subject matter of Claims 24-40, 61-75, 77, 97-111, 113, 127-130, as originally filed in parent U.S. Serial No. 09/191,920, which claims were designated Group II in a restriction requirement, mailed March 24, 2000. The Examiner is respectfully requested to consider the following amendments and remarks.

AMENDMENT

A Version With Markings To Show Changes Made is included beginning at page 10, after Applicant's Remarks.

IN THE SPECIFICATION:

In the Title, at page 1, lines 1-3, please delete the entire title, and insert therefor:

--TRANSFECTION, STORAGE AND TRANSFER OF MALE GERM CELLS FOR  
 GENERATION OF TRANSGENIC SPECIES--.

At page 1, line 4, please delete the entire one-sentence paragraph, and insert the following:

--This application is a division of U.S. Non-provisional Application No. 09/191,920, filed on November 13, 1998, which claims the benefit of U.S. Provisional Application No. 60/065825, filed on November 14, 1997. This application is also related to U.S. Serial

No. \_\_\_\_\_, filed on November 12, 2001, U.S. Serial No. \_\_\_\_\_, filed on November 12, 2001, and U.S. Serial No. \_\_\_\_\_, filed on November 12, 2001, which are all divisions of U.S. Serial No. 09/191,920. This application is also related to U.S. Serial No. 09/272,443, filed March 19, 1999, which is a continuation of 09/191,920.--.

At page 4, line 14 through page 15, line 1, please delete the entire paragraph, and insert therefor the following:

--This invention also relates to a novel method for the isolation of spermatogonia, comprising obtaining spermatogonia from a mixed population of testicular cells by extruding the cells from the seminiferous tubules and gentle enzymatic disaggregation. The spermatogonia or stem cells which are to be genetically modified, may be isolated from a mixed cell population by a novel method including the utilization of a promoter sequence, which is only active in cycling spermatogonia stem cell populations, for example, b-Myb or a spermatogonia specific promoter, such as the c-kit promoter region, c-raf-1 promoter, ATM (ataxia-telangiectasia) promoter, RBM (ribosome binding motif) promoter, DAZ (deleted in azoospermia) promoter, XRCC-1 promoter, HSP 90 (heat shock gene) promoter, or FRMI (from fragile X site) promoter, optionally linked to a reporter construct, for example, the Green Fluorescent Protein Gene (EGFP). These unique promoter sequences drive the expression of the reporter construct only in the cycling spermatogonia. The spermatogonia, thus, are the only cells in the mixed population which will express the reporter construct and they, thus, may be isolated on this basis. In the case of the green fluorescent reporter construct, the cells may be sorted with the aid of, for example, a FACs scanner set at the appropriate wavelength or they may be selected by chemical methods.--.

At page 10, lines 11-17, please delete the entire paragraph and insert therefor the following:

--"Gene delivery (or transfection) mixture", in the context of this patent, means selected genetic material together with an appropriate vector mixed, for example, with an effective amount of lipid transfecting agent. The amount of each component of the mixture is chosen so that the transfection of a specific species of germ cell is optimized. Such optimization requires no more than routine experimentation. The ratio of DNA to lipid is broad, preferably about 1: 1, although other proportions may also be utilized depending on the type of lipid agent and the DNA utilized. This proportion is not crucial.--.

At page 20, lines 15-22, please delete the entire paragraph and insert therefor the following:

--The GFP DNA-transferrin-polylysine viral complexes, prepared as described in Example 4 above, were delivered into the seminiferous tubules of three (3)-week-old B6D2F1 male mice. The DNA delivery by transferrin receptor-mediated endocytosis is described by Schmidt et al. and Wagner et al. (Schmidt et al., Cell 4: 41-51 (1986); Wagner, E., et al. PNAS (1990), (USA) 81: 3410-3414 (1990)). In addition, this delivery system relies on the capacity of adenoviruses to disrupt cell vesicles, such as endosomes and release the contents entrapped therein. The transfection efficiency of this system is almost 2,000 fold higher than lipofection.--.

**IN THE CLAIMS:**

Please cancel Claims 1-134, without prejudice, as originally filed with parent application 09/191,920, and add the following new Claims 135-182 as being directed to the subject matter of designated claim Group II, which is herein elected.

--135.(New) A non-human transgenic vertebrate produced by the steps of:

(a) administering by injection into a testis of a male non-human vertebrate a transfection mixture comprising at least one polynucleotide encoding a gene product in operable linkage with a promoter, and at least one transfecting agent, other than a liposome/DNA complex, wherein said testis contains the germ cells of the male non-human vertebrate, and wherein said germ cells are selected from the group consisting of spermatogonial stem cells, type B spermatogonia, primary spermatocytes, preleptotene spermatocytes, leptotene spermatocytes, zygotene spermatocytes, pachytene spermatocytes, secondary spermatocytes, spermatids, and spermatozoa; and

(b) allowing the polynucleotide encoding a gene product to be taken up by, and released into, the germ cells so that the released polynucleotide is incorporated into the genome of the germ cells of said male non-human vertebrate.

136.(New) The non-human transgenic vertebrate of Claim 135, wherein the polynucleotide comprises at least one biologically functional gene.

137.(New) A progeny non-human transgenic vertebrate, carrying in its germ cells at least one xenogeneic polynucleotide sequence, said non-human vertebrate being obtained by further breeding the male non-human vertebrate of Claim 135 with a female of the same species, and

selecting the bred progeny non-human transgenic vertebrate for the presence of the transfected xenogeneic polynucleotide.

138.(New) The progeny non-human transgenic vertebrate of Claim 137, being a male comprising native germ cells carrying in their genomes at least one xenogeneic polynucleotide.

139.(New) The non-human transgenic vertebrate of Claim 135, which is selected from the group consisting of mammals and birds.

140.(New) The progeny non-human transgenic vertebrate of Claim 137, which is selected from the group consisting of mammals and birds.

141.(New) The non-human transgenic vertebrate of Claim 135, which is a mammal selected from the group consisting of non-human primates, canines, felines, swine, farm and marine mammals, pachyderms, equines, murine, ovines and bovine, or a bird selected from the group consisting of ducks, geese, turkeys and chickens.

142.(New) The non-human transgenic vertebrate of Claim 135, wherein the mammal is selected from the group consisting of wild and domesticated mammals.

143.(New) The non-human transgenic vertebrate of Claim 135, wherein the mammal is a farm or marine animal.

144.(New) The vertebrate of Claim 135, wherein the mammal is selected from the group consisting of a bull and a pig, and the bird is a chicken.

145.(New) A transgenic germ cell, obtained from the non-human transgenic vertebrate of Claim 135.

146.(New) A transgenic germ cell, obtained from the progeny non-human transgenic vertebrate of Claim 137.

147.(New) A transgenic non-human vertebrate male germ cell, obtained by a method comprising performing the method of Claim 135; and then collecting male germ cells produced by the male non-human vertebrate.

148.(New) A transgenic non-human vertebrate male germ cell, obtained by a method comprising performing the method of Claim 137; and then collecting the germ cells produced by the male progeny non-human transgenic vertebrate.

149.(New) Non-human vertebrate semen, comprising the germ cell of Claim 147.

150.(New) Non-human vertebrate semen, comprising the germ cell Claim 148.

151.(New) A method of producing a non-human vertebrate animal line comprising native germ cells carrying in their genome at least one xenogeneic polynucleotide, comprising breeding of the progeny non-human transgenic vertebrate of Claim 137, with a member of the opposite sex of the same species; and selecting progeny for the presence of said polynucleotide.

152.(New) A transgenic non-human vertebrate, comprising germ cells carrying in their genomes at least one xenogeneic polynucleotide, said transgenic non-human vertebrate having received an injection in its testis of male germ cells comprising at least one polynucleotide encoding a desired trait or product and at least one polynucleotide encoding a genetic selection marker, said male germ cells comprising the polynucleotide being isolated or selected from a donor male non-human vertebrate with the aid of the selection marker.

153.(New) The transgenic non-human transgenic vertebrate of Claim 152, wherein the polynucleotide comprises at least one biologically functional gene.

154.(New) A progeny non-human transgenic vertebrate, carrying in its germ cells at least one xenogeneic polynucleotide sequence, said non-human vertebrate being obtained by further breeding the male non-human vertebrate of Claim 152 with a female of the same species, and selecting the bred progeny non-human transgenic vertebrate for the presence of the transfected xenogeneic polynucleotide.

155.(New) The progeny non-human transgenic vertebrate of Claim 154, being a male comprising native male germ cells transfected with a xenogeneic polynucleotide.

156.(New) The non-human transgenic vertebrate of Claim 152, which is selected from the group consisting of mammals and birds.

157.(New) The progeny non-human transgenic vertebrate of Claim 154, which is selected from the group consisting of mammals and birds.

158.(New) The non-human transgenic vertebrate of Claim 152, which is a mammal selected from the group consisting of non-human primates, canines, felines, swine, pachyderms, equines, murine, ovines and bovine, or a bird selected from the group consisting of ducks, geese, turkeys and chickens.

159.(New) The non-human transgenic vertebrate of Claim 152, wherein the mammal is selected from the group consisting of wild and domesticated mammals.

160.(New) The non-human transgenic vertebrate of Claim 152, wherein the mammal is a farm or marine animal.

161.(New) The vertebrate of Claim 152, wherein the mammal is selected from the group consisting of a bull and a pig, and the bird is a chicken.

162.(New) A transgenic germ cell, obtained from the non-human transgenic vertebrate of Claim 152.

163.(New) A transgenic germ cell, obtained from the progeny non-human transgenic vertebrate of Claim 154.

164.(New) A transgenic non-human vertebrate male germ cell, obtained by a method comprising performing the method of Claim 152; and then collecting male germ cells produced by the transgenic male non-human vertebrate.

165.(New) A transgenic non-human vertebrate male germ cell, obtained by a method comprising performing the method of Claim 154; and then collecting the germ cells produced by the male progeny non-human transgenic vertebrate.

166.(New) Non-human vertebrate semen, comprising the germ cell of Claim 164.

167.(New) Non-human vertebrate semen, comprising the germ cell Claim 165.

168.(New) A non-human transgenic vertebrate, or its progeny, comprising a native germ cell carrying in its genome at least one xenogeneic polynucleotide, said polynucleotide having been incorporated into the genome of said germ cell through the steps of:

(a) obtaining a maturing male germ cell from a non-human vertebrate;

(b) transfecting the germ cell in vitro with at least one polynucleotide encoding a desired trait in the presence of a gene delivery mixture comprising at least one transfecting agent, and optionally a polynucleotide encoding a genetic selection marker, at about or below the vertebrate's body temperature and for a transfection-effective period of time; and

allowing the polynucleotide encoding a desired trait to be taken up by, and released into the germ cell.

169.(New) The non-human transgenic vertebrate of Claim 168, wherein the polynucleotide comprises at least one biologically functional gene.

170.(New) The progeny non-human transgenic vertebrate of Claim 168, being a male comprising native male germ cells transfected with a xenogeneic polynucleotide.

171.(New) The non-human transgenic vertebrate of Claim 168, which is selected from the group consisting of mammals and birds.

172.(New) The progeny non-human transgenic vertebrate of Claim 170, which is selected from the group consisting of mammals and birds.

173.(New) The non-human transgenic vertebrate of Claim 168, which is a mammal selected from the group consisting of non-human primates, canines, felines, swine, pachyderms, equines, murine, ovines and bovine, or a bird selected from the group consisting of ducks, geese, turkeys and chickens.

174.(New) The non-human transgenic vertebrate of Claim 168, wherein the mammal is selected from the group consisting of wild and domesticated mammals.

175.(New) The non-human transgenic vertebrate of Claim 168, wherein the mammal is a farm or marine animal.

176.(New) The vertebrate of Claim 168, wherein the mammal is selected from the group consisting of a bull and a pig, and the bird is a chicken.

177.(New) A transgenic germ cell, obtained from the non-human transgenic vertebrate of Claim 168.

178.(New) A transgenic germ cell, obtained from the progeny non-human transgenic vertebrate of Claim 170.

179.(New) A transgenic non-human vertebrate male germ cell, obtained by a method comprising performing the method of Claim 168; and then collecting male germ cells produced by the transgenic male non-human vertebrate.

180.(New) A transgenic non-human vertebrate male germ cell, obtained by a method comprising performing the method of Claim 170; and then collecting the germ cells produced by the male progeny non-human transgenic vertebrate.

181.(New) Non-human vertebrate semen, comprising the germ cell of Claim 179.

182.(New) Non-human vertebrate semen, comprising the germ cell Claim 180--.

### REMARKS

Applicant's Preliminary Amendment is submitted together with a divisional application directed to the subject matter Claims 24-40, 61-75, 77, 97-111, 113, 127-130, as originally filed in pending parent U.S. Serial No. 09/191,920, which claims were designated Group II in a restriction requirement, mailed March 24, 2000.

The amendment of the title (at page 1, lines 1-3), is to bring these into conformity with the new Claims 135-182.


Applicant believes that no new matter is introduced by any amendments made herein.

At page 1, line 4, Applicant has added continuing data explaining the relationship to U.S. Serial No. 09/191,920 and other divisions and continuations thereof.

Applicant's cancellation of Claims 1-134 is made without prejudice. New Claims 135-182 are added. Support is found, e.g., in Claims 24-40, 61-75, 77, 97-111, 113, 127-130 as originally filed.

In view of the above amendments and remarks, it is submitted that this application is now ready for allowance. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney at (213) 896-6665.

Respectfully submitted,



Nisan A. Steinberg, Ph.D.  
Registration No. 40,345

Sidley Austin Brown & Wood  
555 West Fifth Street  
Los Angeles, California 90013-1010  
Telephone: (213) 896-6665  
Facsimile: (213) 896-6600

VERSION WITH MARKINGS TO SHOW CHANGES MADEIN THE SPECIFICATION:

In the Title, at page 1, lines 1-3, please delete the entire title, and insert therefor:

--TRANSFECTION, STORAGE AND TRANSFER OF MALE GERM CELLS FOR  
GENERATION OF TRANSGENIC SPECIES [& GENETIC THERAPIES]--.

At page 1, line 4, please delete the entire one-sentence paragraph, and insert the following:

--This application is a division of U.S. Non-provisional Application No. 09/191,920, filed on November 13, 1998, which claims the benefit of U.S. Provisional Application No. 60/065825, filed on November 14, 1997. This application is also related to U.S. Serial No. , filed on November 12, 2001, U.S. Serial No. , filed on November 12, 2001, and U.S. Serial No. , filed on November 12, 2001, which are all divisions of U.S. Serial No. 09/191,920. This application is also related to U.S. Serial No. 09/272,443, filed March 19, 1999, which is a continuation of 09/191,920.--

At page 4, line 14 through page 15, line 1, please delete the entire paragraph, and insert therefor the following:

--This invention also relates to a novel method for the isolation of spermatogonia, comprising obtaining spermatogonia from a mixed population of testicular cells by extruding the cells from the seminiferous tubules and gentle enzymatic disaggregation. The spermatogonia or stem cells which are to be genetically modified, may be isolated from a mixed cell population by a novel method including the utilization of a promoter sequence, which is only active in cycling spermatogonia stem cell populations, for example, b-Myb or a spermatogonia specific promoter, such as the c-kit promoter region, c-raf-1 promoter, ATM ([ataxia]ataxia-telangiectasia) promoter, RBM (ribosome binding motif) promoter, DAZ (deleted in azoospermia) promoter, XRCC-1 promoter, HSP 90 (heat shock gene) promoter, or FRMI (from fragile X site) promoter, optionally linked to a reporter construct, for example, the Green Fluorescent Protein Gene (EGFP). These unique promoter sequences drive the expression of the reporter construct only in the cycling spermatogonia. The spermatogonia, thus, are the only cells in the mixed population which will express the reporter construct and they, thus, may be isolated on this basis. In the case of the green

fluorescent reporter construct, the cells may be sorted with the aid of, for example, a FACS scanner set at the appropriate wavelength or they may be selected by chemical methods.--.

At page 10, lines 11-17, please delete the entire paragraph and insert therefor the following:

--"Gene delivery (or transfection) mixture", in the context of this patent, means selected genetic material together with an appropriate vector mixed, for example, with an effective amount of lipid transfect[ion]ing agent. The amount of each component of the mixture is chosen so that the transfection of a specific species of germ cell is optimized. Such optimization requires no more than routine experimentation. The ratio of DNA to lipid is broad, preferably about 1: 1, although other proportions may also be utilized depending on the type of lipid agent and the DNA utilized. This proportion is not crucial.--.

At page 20, lines 15-22, please delete the entire paragraph and insert therefor the following:

--The GFP DNA-transferrin-polylysine viral complexes, prepared as described in Example 4 above, were delivered into the seminiferous tubules of three (3)-week-old B6D2F1 male mice. The DNA delivery by transferrin receptor-mediated endocytosis is described by Schmidt et al. and Wagner et al. (Schmidt et al., Cell 4: 41-51 (1986); Wagner, E., et al. PNAS (1990), (USA) 81: 3410-3414 (1990)). In addition, this delivery system relies on the capacity of adenoviruses to disrupt cell vesicles, such as endosomes and release the contents entrapped therein. The transfection efficiency of this system is almost 2,000 fold higher than lipofection.--.

IN THE CLAIMS:

Please cancel Claims 1-134, without prejudice, as originally filed with parent application 09/191,920, and add the following new Claims 135-182 as being directed to the subject matter of designated claim Group II, which is herein elected.

--135.(New) A non-human transgenic vertebrate produced by the steps of:

(a) administering by injection into a testis of a male non-human vertebrate a transfection mixture comprising at least one polynucleotide encoding a gene product in operable linkage with a promoter, and at least one transfecting agent, other than a liposome/DNA complex, wherein said testis contains the germ cells of the male non-human vertebrate, and wherein said germ

cells are selected from the group consisting of spermatogonial stem cells, type B spermatogonia, primary spermatocytes, preleptotene spermatocytes, leptotene spermatocytes, zygotene spermatocytes, pachytene spermatocytes, secondary spermatocytes, spermatids, and spermatozoa; and

(b) allowing the polynucleotide encoding a gene product to be taken up by, and released into, the germ cells so that the released polynucleotide is incorporated into the genome of the germ cells of said male non-human vertebrate.

136.(New) The non-human transgenic vertebrate of Claim 135, wherein the polynucleotide comprises at least one biologically functional gene.

137.(New) A progeny non-human transgenic vertebrate, carrying in its germ cells at least one xenogeneic polynucleotide sequence, said non-human vertebrate being obtained by further breeding the male non-human vertebrate of Claim 135 with a female of the same species, and selecting the bred progeny non-human transgenic vertebrate for the presence of the transfected xenogeneic polynucleotide.

138.(New) The progeny non-human transgenic vertebrate of Claim 137, being a male comprising native germ cells carrying in their genomes at least one xenogeneic polynucleotide.

139.(New) The non-human transgenic vertebrate of Claim 135, which is selected from the group consisting of mammals and birds.

140.(New) The progeny non-human transgenic vertebrate of Claim 137, which is selected from the group consisting of mammals and birds.

141.(New) The non-human transgenic vertebrate of Claim 135, which is a mammal selected from the group consisting of non-human primates, canines, felines, swine, farm and marine mammals, pachyderms, equines, murine, ovines and bovine, or a bird selected from the group consisting of ducks, geese, turkeys and chickens.

142.(New) The non-human transgenic vertebrate of Claim 135, wherein the mammal is selected from the group consisting of wild and domesticated mammals.

143.(New) The non-human transgenic vertebrate of Claim 135, wherein the mammal is a farm or marine animal.

144.(New) The vertebrate of Claim 135, wherein the mammal is selected from the group consisting of a bull and a pig, and the bird is a chicken.

145.(New) A transgenic germ cell, obtained from the non-human transgenic vertebrate of Claim 135.

146.(New) A transgenic germ cell, obtained from the progeny non-human transgenic vertebrate of Claim 137.

147.(New) A transgenic non-human vertebrate male germ cell, obtained by a method comprising performing the method of Claim 135; and then collecting male germ cells produced by the male non-human vertebrate.

148.(New) A transgenic non-human vertebrate male germ cell, obtained by a method comprising performing the method of Claim 137; and then collecting the germ cells produced by the male progeny non-human transgenic vertebrate.

149.(New) Non-human vertebrate semen, comprising the germ cell of Claim 147.

150.(New) Non-human vertebrate semen, comprising the germ cell Claim 148.

151.(New) A method of producing a non-human vertebrate animal line comprising native germ cells carrying in their genome at least one xenogeneic polynucleotide, comprising breeding of the progeny non-human transgenic vertebrate of Claim 137, with a member of the opposite sex of the same species; and selecting progeny for the presence of said polynucleotide.

152.(New) A transgenic non-human vertebrate, comprising germ cells carrying in their genomes at least one xenogeneic polynucleotide, said transgenic non-human vertebrate having received an injection in its testis of male germ cells comprising at least one polynucleotide encoding a desired trait or product and at least one polynucleotide encoding a genetic selection marker, said male germ cells comprising the polynucleotide being isolated or selected from a donor male non-human vertebrate with the aid of the selection marker.

153.(New) The transgenic non-human transgenic vertebrate of Claim 152, wherein the polynucleotide comprises at least one biologically functional gene.

154.(New) A progeny non-human transgenic vertebrate, carrying in its germ cells at least one xenogeneic polynucleotide sequence, said non-human vertebrate being obtained by further breeding the male non-human vertebrate of Claim 152 with a female of the same species, and selecting the bred progeny non-human transgenic vertebrate for the presence of the transfected xenogeneic polynucleotide.

155.(New) The progeny non-human transgenic vertebrate of Claim 154, being a male comprising native male germ cells transfected with a xenogeneic polynucleotide.

156.(New) The non-human transgenic vertebrate of Claim 152, which is selected from the group consisting of mammals and birds.

157.(New) The progeny non-human transgenic vertebrate of Claim 154, which is selected from the group consisting of mammals and birds.

158.(New) The non-human transgenic vertebrate of Claim 152, which is a mammal selected from the group consisting of non-human primates, canines, felines, swine, pachyderms, equines, murine, ovines and bovine, or a bird selected from the group consisting of ducks, geese, turkeys and chickens.

159.(New) The non-human transgenic vertebrate of Claim 152, wherein the mammal is selected from the group consisting of wild and domesticated mammals.

160.(New) The non-human transgenic vertebrate of Claim 152, wherein the mammal is a farm or marine animal.

161.(New) The vertebrate of Claim 152, wherein the mammal is selected from the group consisting of a bull and a pig, and the bird is a chicken.

162.(New) A transgenic germ cell, obtained from the non-human transgenic vertebrate of Claim 152.

163.(New) A transgenic germ cell, obtained from the progeny non-human transgenic vertebrate of Claim 154.

164.(New) A transgenic non-human vertebrate male germ cell, obtained by a method comprising performing the method of Claim 152; and then collecting male germ cells produced by the transgenic male non-human vertebrate.

165.(New) A transgenic non-human vertebrate male germ cell, obtained by a method comprising performing the method of Claim 154; and then collecting the germ cells produced by the male progeny non-human transgenic vertebrate.

166.(New) Non-human vertebrate semen, comprising the germ cell of Claim 164.

167.(New) Non-human vertebrate semen, comprising the germ cell Claim 165.

168.(New) A non-human transgenic vertebrate, or its progeny, comprising a native germ cell carrying in its genome at least one xenogeneic polynucleotide, said polynucleotide having been incorporated into the genome of said germ cell through the steps of:

(a) obtaining a maturing male germ cell from a non-human vertebrate;

(b) transfecting the germ cell in vitro with at least one polynucleotide encoding a desired trait in the presence of a gene delivery mixture comprising at least one transfecting agent, and optionally a polynucleotide encoding a genetic selection marker, at about or below the vertebrate's body temperature and for a transfection-effective period of time; and

allowing the polynucleotide encoding a desired trait to be taken up by, and released into the germ cell.

169.(New) The non-human transgenic vertebrate of Claim 168, wherein the polynucleotide comprises at least one biologically functional gene.

170.(New) The progeny non-human transgenic vertebrate of Claim 168, being a male comprising native male germ cells transfected with a xenogeneic polynucleotide.

171.(New) The non-human transgenic vertebrate of Claim 168, which is selected from the group consisting of mammals and birds.

172.(New) The progeny non-human transgenic vertebrate of Claim 170, which is selected from the group consisting of mammals and birds.

173.(New) The non-human transgenic vertebrate of Claim 168, which is a mammal selected from the group consisting of non-human primates, canines, felines, swine, pachyderms, equines, murine, ovines and bovine, or a bird selected from the group consisting of ducks, geese, turkeys and chickens.

174.(New) The non-human transgenic vertebrate of Claim 168, wherein the mammal is selected from the group consisting of wild and domesticated mammals.

175.(New) The non-human transgenic vertebrate of Claim 168, wherein the mammal is a farm or marine animal.

176.(New) The vertebrate of Claim 168, wherein the mammal is selected from the group consisting of a bull and a pig, and the bird is a chicken.

177.(New) A transgenic germ cell, obtained from the non-human transgenic vertebrate of Claim 168.

178.(New) A transgenic germ cell, obtained from the progeny non-human transgenic vertebrate of Claim 170.

179.(New) A transgenic non-human vertebrate male germ cell, obtained by a method comprising performing the method of Claim 168; and then collecting male germ cells produced by the transgenic male non-human vertebrate.

180.(New) A transgenic non-human vertebrate male germ cell, obtained by a method comprising performing the method of Claim 170; and then collecting the germ cells produced by the male progeny non-human transgenic vertebrate.

181.(New) Non-human vertebrate semen, comprising the germ cell of Claim 179.

182.(New) Non-human vertebrate semen, comprising the germ cell Claim 180.--.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Date, March 19, 1999

In re application of: Readhead et al.  
 Serial No. 09/191,920  
 Filed: November 13, 1998  
 For: TRANSFECTION STORAGE AND TRANSFER OF MALE GERM  
 CELLS FOR GENERATION OF TRANSGENIC SPECIES &  
 GENETIC THERAPIES  
 Examiner: Unassigned  
 Unit: 1643

PRELIMINARY AMENDMENT

Assistant Commissioner for  
 Patents  
 Washington, D. C. 20231

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED  
 WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN  
 ENVELOPE ADDRESSED TO THE ASSISTANT COMMISSIONER FOR PATENTS  
 WASHINGTON, D. C. 20231, ON March 19, 1999  
 BY ANN WEISS DATE  
March 19, 1999  
 DATE OF SIGNATURE

Dear Sir:

In connection with the above-captioned application, please enter the  
 following amendments:

In the Specification:

Page 10, line 13, change "transfection agent" to --transfected agent--.

Page 20, line 18, change "Schmit" to --Schmidt-- in the two places it  
 appears.

In the claims:

Please cancel claims 126 through 130 without prejudice

Please amend the following claim as follows:

114. (Amended) A kit for the transfection [and storage] of a male vertebrate's germ cells, [comprising] containing the component(s) of a transfection mixture, [said transfection mixture] comprising at least one transfecting agent, and optionally a genetic selection marker, whereby said kit may be used to transfect [and store] said germ cells [in a viable condition].

Request is made for correction of inventorship under 37 C.F.R. §1.48(b), deleting the name of OUTI HOVATTA.

Request has also been made to the Application Processing Division's Customer Correction Branch to place Carol W. Readhead, Pasadena, CA as the first inventor, followed by Robert Winston, London, United Kingdom, as they appeared on the cover page of the application filed November 13, 1998.

REMARKS

The amendment at page 10, line 13, is supported, for example, at page 10, lines 18 and 22.

The amendment to claim 114 is supported, for example, at page 5, lines 25-28

The amendment at page 20, line 18 is to correct a typographical error.


Deletion of **OUT HOVATTA** from this application is made necessary by the cancellation of claims 126 through 130 (and the amendment to claim 114). Dr. Hovatta is not a co-inventor of the remaining claims.

This is also stated in the accompanying petition filed in compliance with 37 C.F.R. § 1.48(b)(1). Payment of the requisite fee under 37 C.F.R. 1.17(i) is made herewith in compliance with 37 C.F.R. § 1.48(b)(2).

Therefore, a first office action not having been received, applicants respectfully request that these preliminary amendments be entered.

Respectfully submitted,

PRETTY, SCHROEDER & POPLAWSKI, P.C.

By: 

Nisan A. Steinberg, Ph.D.  
Reg. No. 40,345

444 South Flower Street -19<sup>th</sup> Floor  
Los Angeles, California 90071-2909  
Ofc: 213/ 622-7700  
Fax: 213/489-4210  
ODMA\PCDOCS\DOCS\414\1